Latest action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 520.
Committee has approved the bill (usually with amendments) and sent it back to the full chamber.
The committee voted to send the bill to the floor of the full chamber. The Senate Majority Leader schedules a floor vote.
Next: Passed One Chamber
The other chamber (Senate or House) repeats the committee + floor-vote process
Bill speeds up approval and availability of cheaper biosimilar drugs in America.
The problem
Biosimilar drugs take too long to reach patients. High drug prices burden consumers and healthcare systems seeking affordable alternatives to expensive brand-name biologics.
The proposal
The bill streamlines FDA approval processes for biosimilar medications and removes regulatory barriers to faster market entry and patient access.
The impact
Patients gain faster access to affordable drug options. Pharmaceutical companies face quicker competition. Healthcare costs may decrease for insurers and patients.
Biosimilars are cheaper versions of expensive biologics. Faster approval means patients and insurers pay less for medications sooner. This reduces healthcare spending nationwide.
More people can afford needed medications when biosimilars reach market quickly. Patients get treatment options faster instead of waiting years.
More biosimilars competing removes monopolies held by brand-name drug makers. Competition drives prices down and encourages innovation.
Streamlined approval processes let the FDA handle more applications efficiently. Resources focus on safety while removing unnecessary delays.
Faster approvals might reduce thorough safety testing of biosimilars. Rushing could miss side effects or quality problems discovered later.
Brand-name drug companies lose revenue when biosimilars enter market quickly. Companies might reduce research spending on new medications.
Expedited timelines could allow lower-quality biosimilars to reach patients. Reduced oversight might lead to inconsistent drug manufacturing standards.
The bill summary is unavailable, making specifics unknown. Exact regulatory changes and enforcement details remain unclear to evaluate.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.